Zinc-Dependent Histone Deacetylases in Lung Endothelial Pathobiology

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2024 Feb 24

PMID 38397377

Authors

Rahul S Patil

McKenzie E Maloney

Rudolf Lucas

David J R Fulton

Vijay Patel

Zsolt Bagi

Anita Kovacs-Kasa

Laszlo Kovacs

Yunchao Su

Alexander D Verin

Affiliations

Soon will be listed here.

Abstract

A monolayer of endothelial cells (ECs) lines the lumen of blood vessels and, as such, provides a semi-selective barrier between the blood and the interstitial space. Compromise of the lung EC barrier due to inflammatory or toxic events may result in pulmonary edema, which is a cardinal feature of acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS). The EC functions are controlled, at least in part, via epigenetic mechanisms mediated by histone deacetylases (HDACs). Zinc-dependent HDACs represent the largest group of HDACs and are activated by Zn. Members of this HDAC group are involved in epigenetic regulation primarily by modifying the structure of chromatin upon removal of acetyl groups from histones. In addition, they can deacetylate many non-histone histone proteins, including those located in extranuclear compartments. Recently, the therapeutic potential of inhibiting zinc-dependent HDACs for EC barrier preservation has gained momentum. However, the role of specific HDAC subtypes in EC barrier regulation remains largely unknown. This review aims to provide an update on the role of zinc-dependent HDACs in endothelial dysfunction and its related diseases. We will broadly focus on biological contributions, signaling pathways and transcriptional roles of HDACs in endothelial pathobiology associated mainly with lung diseases, and we will discuss the potential of their inhibitors for lung injury prevention.

Citing Articles

Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory Diseases.

Theodoropoulou M, Mantzourani C, Kokotos G Biomolecules. 2025; 14(12.

PMID: 39766311 PMC: 11674560. DOI: 10.3390/biom14121605.

Inhalable and bioactive lipid-nanomedicine based on bergapten for targeted acute lung injury therapy via orchestrating macrophage polarization.

Liao R, Sun Z, Wang L, Xian C, Lin R, Zhuo G Bioact Mater. 2024; 43:406-422.

PMID: 39411684 PMC: 11474395. DOI: 10.1016/j.bioactmat.2024.09.020.

Investigating Potential Cancer Therapeutics: Insight into Histone Deacetylases (HDACs) Inhibitions.

Ahmad B, Saeed A, Al-Amery A, Celik I, Ahmed I, Yaseen M Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675404 PMC: 11054547. DOI: 10.3390/ph17040444.

A Molecular Hybrid of the GFP Chromophore and 2,2'-Bipyridine: An Accessible Sensor for Zn Detection with Fluorescence Microscopy.

Csomos A, Madarasz M, Turczel G, Cseri L, Katona G, Rozsa B Int J Mol Sci. 2024; 25(6).

PMID: 38542479 PMC: 10971390. DOI: 10.3390/ijms25063504.

References

Das Gupta K, Shakespear M, Curson J, Murthy A, Iyer A, Hodson M . Class IIa Histone Deacetylases Drive Toll-like Receptor-Inducible Glycolysis and Macrophage Inflammatory Responses via Pyruvate Kinase M2. Cell Rep. 2020; 30(8):2712-2728.e8. DOI: 10.1016/j.celrep.2020.02.007. View

Ito K, Caramori G, Lim S, Oates T, Chung K, Barnes P . Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med. 2002; 166(3):392-6. DOI: 10.1164/rccm.2110060. View

Kee H, Kook H . Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy. J Biomed Biotechnol. 2010; 2011:928326. PMC: 2997602. DOI: 10.1155/2011/928326. View

Nomura Y, Nakano M, Sung H, Han M, Pandey D . Inhibition of HDAC6 Activity Protects Against Endothelial Dysfunction and Atherogenesis : A Role for HDAC6 Neddylation. Front Physiol. 2021; 12:675724. PMC: 8245780. DOI: 10.3389/fphys.2021.675724. View

Bedenbender K, Scheller N, Fischer S, Leiting S, Preissner K, Schmeck B . Inflammation-mediated deacetylation of the ribonuclease 1 promoter histone deacetylase 2 in endothelial cells. FASEB J. 2019; 33(8):9017-9029. DOI: 10.1096/fj.201900451R. View

Liu L, Zhou X, Shetty S, Hou G, Wang Q, Fu J . HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury. Toxicol Appl Pharmacol. 2019; 370:178-183. DOI: 10.1016/j.taap.2019.03.017. View

Fischer D, Cai R, Bhatia U, Asselbergs F, Song C, Terry R . Isolation and characterization of a novel class II histone deacetylase, HDAC10. J Biol Chem. 2001; 277(8):6656-66. DOI: 10.1074/jbc.M108055200. View

Bahl S, Seto E . Regulation of histone deacetylase activities and functions by phosphorylation and its physiological relevance. Cell Mol Life Sci. 2020; 78(2):427-445. PMC: 7854769. DOI: 10.1007/s00018-020-03599-4. View

Yoon S, Eom G . HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Med J. 2016; 52(1):1-11. PMC: 4742605. DOI: 10.4068/cmj.2016.52.1.1. View

10.

Usui T, Okada M, Mizuno W, Oda M, Ide N, Morita T . HDAC4 mediates development of hypertension via vascular inflammation in spontaneous hypertensive rats. Am J Physiol Heart Circ Physiol. 2012; 302(9):H1894-904. DOI: 10.1152/ajpheart.01039.2011. View

11.

Dejana E, Orsenigo F, Lampugnani M . The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci. 2008; 121(Pt 13):2115-22. DOI: 10.1242/jcs.017897. View

12.

Su Y, Tan R, Sun M, Yuan L, Ruiz M, Dupuis J . MiR-1249 on Endothelial Extracellular Vesicles Mediates Cigarette Smoke-Induced Pulmonary Hypertension by Inhibiting HDAC10 (Histone Deacetylase 10)-NFκB (Nuclear Factor κB)-CaSR (Calcium-Sensing Receptor) Cascade. Hypertension. 2022; 79(12):2721-2732. DOI: 10.1161/HYPERTENSIONAHA.122.19560. View

13.

Chen L, Shang C, Wang B, Wang G, Jin Z, Yao F . HDAC3 inhibitor suppresses endothelial-to-mesenchymal transition via modulating inflammatory response in atherosclerosis. Biochem Pharmacol. 2021; 192:114716. DOI: 10.1016/j.bcp.2021.114716. View

14.

He M, Zhang B, Wei X, Wang Z, Fan B, Du P . HDAC4/5-HMGB1 signalling mediated by NADPH oxidase activity contributes to cerebral ischaemia/reperfusion injury. J Cell Mol Med. 2013; 17(4):531-42. PMC: 3822653. DOI: 10.1111/jcmm.12040. View

15.

Rajendrasozhan S, Yang S, Edirisinghe I, Yao H, Adenuga D, Rahman I . Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. Antioxid Redox Signal. 2008; 10(4):799-811. PMC: 2758554. DOI: 10.1089/ars.2007.1938. View

16.

Leus N, van der Wouden P, van den Bosch T, Hooghiemstra W, Ourailidou M, Kistemaker L . HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-κB p65 transcriptional activity. Biochem Pharmacol. 2016; 108:58-74. PMC: 4844503. DOI: 10.1016/j.bcp.2016.03.010. View

17.

King J, Patel M, Chandrasekaran S . Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective. Metabolites. 2021; 11(11). PMC: 8620738. DOI: 10.3390/metabo11110792. View

18.

Thangavel J, Malik A, Elias H, Rajasingh S, Simpson A, Sundivakkam P . Combinatorial therapy with acetylation and methylation modifiers attenuates lung vascular hyperpermeability in endotoxemia-induced mouse inflammatory lung injury. Am J Pathol. 2014; 184(8):2237-49. PMC: 4116699. DOI: 10.1016/j.ajpath.2014.05.008. View

19.

Kovacs-Kasa A, Gorshkov B, Kim K, Kumar S, Black S, Fulton D . The protective role of MLCP-mediated ERM dephosphorylation in endotoxin-induced lung injury in vitro and in vivo. Sci Rep. 2016; 6:39018. PMC: 5157034. DOI: 10.1038/srep39018. View

20.

Ning L, Rui X, Bo W, Qing G . The critical roles of histone deacetylase 3 in the pathogenesis of solid organ injury. Cell Death Dis. 2021; 12(8):734. PMC: 8302660. DOI: 10.1038/s41419-021-04019-6. View